Bejarano PF
Pain Medicine Section, Department of Anesthesiology, Fundación Santa Fe de Bogotá, Santafé de Bogotá, Colombia.
Curr Rev Pain. 1999;3(6):432-439. doi: 10.1007/s11916-999-0070-5.
The discovery that two cyclooxygenase (COX) isoenzymes, including inducible forms (COX-2), could be selectively inhibited has triggered new research to develop selective inhibitors. During this process, pharmacotherapeutic concepts in inflammatory pain, and clinicians over-expectations, have created some degree of uncertainty for clinicians about the promise of COX-2 inhibitors and the real role they play. The purpose of this article is to critically review, within the context of NSAIDs, some of the old and new concepts in the management of inflammatory pain, as well as to examine the current evidence of the usefulness of COX-2 inhibitors today.
发现包括诱导型(COX-2)在内的两种环氧化酶(COX)同工酶能够被选择性抑制,这引发了研发选择性抑制剂的新研究。在此过程中,炎症性疼痛的药物治疗理念以及临床医生过高的期望,给临床医生在COX-2抑制剂的前景及其实际作用方面带来了一定程度的不确定性。本文旨在非甾体抗炎药(NSAIDs)的背景下,批判性地回顾炎症性疼痛管理中的一些新旧概念,并审视目前关于COX-2抑制剂有效性的证据。